{"id":"NCT02877927","sponsor":"Paratek Pharmaceuticals Inc","briefTitle":"Oral Omadacycline vs. Oral Linezolid for the Treatment of ABSSSI","officialTitle":"A Phase 3 Randomized, Double-Blind, Multi-Center Study to Compare the Safety and Efficacy of Oral Omadacycline to Oral Linezolid for Treating Adult Subjects With Acute Bacterial Skin and Skin Structure Infection (ABSSSI)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2016-08","primaryCompletion":"2017-05-26","completion":"2017-06-06","firstPosted":"2016-08-24","resultsPosted":"2018-11-30","lastUpdate":"2018-11-30"},"enrollment":735,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Bacterial Infections","Skin Structures and Soft Tissue Infections"],"interventions":[{"type":"DRUG","name":"Omadacycline","otherNames":[]},{"type":"DRUG","name":"Linezolid","otherNames":["Zyvox"]}],"arms":[{"label":"Omadacycline","type":"EXPERIMENTAL"},{"label":"Linezolid","type":"ACTIVE_COMPARATOR"}],"summary":"The purpose of this study is to evaluate the safety and efficacy of omadacycline as compared to linezolid in the treatment of adults with acute bacterial skin and skin structure infections.","primaryOutcome":{"measure":"Number of Participants With Early Clinical Response","timeFrame":"Screening; 48 to 72 hours after the first dose of test article","effectByArm":[{"arm":"Omadacycline","deltaMin":315,"sd":null},{"arm":"Linezolid","deltaMin":297,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":null}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":7},"locations":{"siteCount":50,"countries":["United States"]},"refs":{"pmids":["39461915","35776862","33458763","33326848","31474458","31367742"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":5,"n":368},"commonTop":["Nausea","Vomiting","Wound infection","Alanine aminotransferase increased","Aspartate aminotransferase increased"]}}